Blair William & Co. IL Has $28.88 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Blair William & Co. IL lowered its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,261,677 shares of the biopharmaceutical company’s stock after selling 89,031 shares during the quarter. Blair William & Co. IL’s holdings in Dynavax Technologies were worth $28,882,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of DVAX. E Fund Management Co. Ltd. raised its position in Dynavax Technologies by 4.6% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 771 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 1,109 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 1,457 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in shares of Dynavax Technologies by 463.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Stock Up 1.0 %

Dynavax Technologies stock opened at $13.72 on Friday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $1.70 billion, a P/E ratio of 76.22 and a beta of 1.23. The firm has a 50 day moving average price of $13.32 and a 200-day moving average price of $12.47. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.